philipn / COVID-19 therapeutics 0cb17ff62efa7df68760554578bf183cb60cdba2

Create Draft
Linking Amodiaquine
Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this

Theraputics are medications/treatments designed to combat an infection. This is in contrast to vaccines, which prevent a disease from occuring. As vaccines may not be widely available for some time, theraputics for COVID-19 could play an important role in the epidemic.

This page details potential COVID-19 theraputics. Substances listed here are not necessarily effective. Potential medications are detailed because they are on trial for use in COVID-19 or have been described as a potential treatment in an academic paper.

Anti-virals

Potential neutralizing strategies as described in "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Photo CC-BY Robert L. Kruse.
  • Convalescent plasma
  • Remdesivir
  • MK-4482 (formerly known as EIDD-2801)
  • Favipiravir
  • Hydroxychloroquine and Chloroquine
  • Dipyridamole
  • Niclosamide
  • Nitazoxanide
  • Doxycycyline
  • Ciclesonide
  • Interferons
  • Camostat mesylate
  • Indomethacin
  • Bromhexine
  • Galidesivir
  • Monoclonal Antibodies
  • Soluable ACE2 / ACE2-fc

Host response / anti-inflammatory

  • Dexamethasone
  • Tocilizumab
  • Heparin / enoxaparin
  • ARBs
  • Baricitinib

See also

Theraputics are medications/treatments designed to combat an infection. This is in contrast to vaccines, which prevent a disease from occuring. As vaccines may not be widely available for some time, theraputics for COVID-19 could play an important role in the epidemic.

This page details potential COVID-19 theraputics. Substances listed here are not necessarily effective. Potential medications are detailed because they are on trial for use in COVID-19 or have been described as a potential treatment in an academic paper.

Anti-virals

Potential neutralizing strategies as described in "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Photo CC-BY Robert L. Kruse.
  • Convalescent plasma
  • Remdesivir
  • MK-4482 (formerly known as EIDD-2801)
  • Favipiravir
  • Hydroxychloroquine and Chloroquine
  • Dipyridamole
  • Niclosamide
  • Nitazoxanide
  • Doxycycyline
  • Ciclesonide
  • Interferons
  • Camostat mesylate
  • Indomethacin
  • Bromhexine
  • Galidesivir
  • Monoclonal Antibodies
  • Amodiaquine
  • Soluable ACE2 / ACE2-fc

Host response / anti-inflammatory

  • Dexamethasone
  • Tocilizumab
  • Heparin / enoxaparin
  • ARBs
  • Baricitinib

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.